Although matrix metalloproteinase (MMP) expression is found to be elevated after acute coronary syndrome (ACS), the slow elevation of MMP levels and the lack of clinical outcome data do not currently make MMPs useful biomarkers for therapeutic decision making or risk stratification in ACS. They do, however, remain an active area of investigation as a therapeutic target.